Melanoma patients have a type of cancer that generally falls into one of two groups, based on a gene call BRAF. The goal of the SU2C–Melanoma Research Alliance (MRA) Melanoma Dream Team is to examine the entire set of genetic instructions (called the genome) of metastatic melanoma patients whose tumors do not have mutations in their BRAF gene. The team wants to understand the characteristics of each patient’s genome in order to select therapies that are more precisely targeted to the individual.